%PDF-1.4
%
100 0 obj
<>
endobj
97 0 obj
<>
endobj
267 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T18:00:47Z
2024-03-28T03:06:26-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T03:06:26-07:00
application/pdf
Heather
2001-533.may
uuid:d80425a2-1dd1-11b2-0a00-110a278d5b00
uuid:d80425a4-1dd1-11b2-0a00-1e0000000000
endstream
endobj
86 0 obj
<>
endobj
87 0 obj
<>
endobj
101 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
27 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
40 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
63 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
71 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
298 0 obj
[303 0 R]
endobj
299 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
55 54 m
559 54 l
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:5)Tj
0 Tw -46.2952 -0.0313 Td
(972)Tj
ET
0 0 0 0 scn
/GS0 gs
101.08 59.11 407.5 -10.83 re
f*
0.5 w
101.08 59.11 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.0249 Tw 8 0 0 8 71 714.5293 Tm
[(spondylitis patients with the general population. )55 (Arthritis Rheum)]TJ
0 Tw 0 -1.25 TD
(1984;27:361-8.)Tj
0.02499 Tw -1.25 -1.25 Td
[(5.)-500 (Germain RN. MHC-dependent antigen processing and peptide)]TJ
1.25 -1.25 Td
[(presentation: providing ligands for )18 (T)-257 (lymphocyte activation. Cell)]TJ
0 Tw T*
(1994;76:287-99.)Tj
-0.00011 Tc 0.02499 Tw -1.25 -1.25 Td
[(6.)-500 (Madden DR, Gor)18 (ga JC, Strominger JL, )18 (W)40 (iley DC. )18 (The three-)]TJ
0 Tc 1.25 -1.25 Td
[(dimensional structure of HLA-B27 at 2.1 )55 (A)-220 (resolution suggest a)]TJ
T*
(general mechanism for tight peptide binding to MHC. Cell)Tj
0 Tw T*
(1992;70:1035-48.)Tj
0.02499 Tw -1.25 -1.25 Td
[(7.)-500 (Jardetzky )18 (TS, Lane )18 (WS, Robinson RA, Madden DR, )18 (W)40 (iley DC.)]TJ
1.25 -1.25 Td
(Identification of self peptides bound to purified HLA-B27. Nature)Tj
0 Tw T*
(1991;353:326-9.)Tj
0.02499 Tw -1.25 -1.25 Td
[(8.)-500 (Rock KL, Gamble S, Rothstein L, Gramm C, Benacerraf B.)]TJ
1.25 -1.25 Td
(Dissociation of beta 2-microglobulin leads to the accumulation of a)Tj
T*
(substantial pool of inactive class I MHC heavy chains on the cell)Tj
T*
[(surface. Cell 1990;65:61)37 (1-20.)]TJ
-1.25 -1.25 Td
[(9.)-500 (Carreno BM, Hansen )18 (TH. Exogenous peptide ligand influences the)]TJ
-0.00011 Tc 1.25 -1.25 Td
[(expression and half-life of free HLA)-220 (class I heavy chains)]TJ
0 Tc T*
(ubiquitously detected at the cell surface. Eur J Immunol)Tj
0 Tw T*
(1994;24:1285-92.)Tj
0.02499 Tw -1.75 -1.25 Td
[(10.)-500 (Sijts )55 (AJ, Pamer EG. Enhanced intracellular dissociation of major)]TJ
1.75 -1.25 Td
(histocompatibility complex class I-associated peptides: a mechanism)Tj
T*
[(for optimizing the spectrum of cell surface-presented cytotoxic )18 (T)]TJ
T*
[(lymphocyte epitopes. J Exp Med 1997;185:1403-1)37 (1.)]TJ
-1.7131 -1.25 Td
[(1)37 (1.)-500 (Allen RL, O\222Callaghan CA, McMichael )55 (AJ, Bowness P)111 (. Cutting)]TJ
1.7131 -1.25 Td
(edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy)Tj
T*
(chain homodimer structure. J Immunol 1999;162:5045-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(12.)-500 (Hammer RE, Maika SD, Richardson JA, )18 (T)70 (ang J-P)111 (, )18 (T)70 (aurog JD.)]TJ
0 Tc 1.75 -1.25 Td
(Spontaneous inflammatory disease in transgenic rat expressing)Tj
T*
(HLA-B27 and human \337)Tj
0 Tw 5.2 0 0 5.2 147.3598 421.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 149.9598 424.5293 Tm
(m: an animal model of HLA-B27 associated)Tj
-9.87 -1.25 Td
[(human disorders. Cell 1990;63:1099-1)37 (12.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(13.)-500 (Khare SD, Luthra HS, David CS. Spontaneous arthritis in HLA-B27)]TJ
0 Tc 1.75 -1.25 Td
(transgenic mice lacking \337)Tj
0 Tw 5.2 0 0 5.2 153.5649 391.8893 Tm
(2)Tj
0.02499 Tw 8 0 0 8 156.1649 394.5293 Tm
(-microglobulin: a model of human)Tj
-10.6456 -1.25 Td
[(spondyloarthropathies. J Exp Med 1995;182:1)37 (153-8.)]TJ
-1.75 -1.25 Td
[(14.)-500 (Kingsbury DJ, Mear JP)111 (, )18 (W)40 (itte DP)111 (, )18 (T)70 (aurog JD, Roopenian DC,)]TJ
1.75 -1.25 Td
(Colbert RA. Development of spontaneous arthritis in )Tj
0 Tw T*
(\337)Tj
5.2 0 0 5.2 75 351.8893 Tm
(2)Tj
0.0249 Tw 8 0 0 8 77.6 354.5293 Tm
(-microglobulin-deficient mice without expression of HLA-B27.)Tj
-0.825 -1.25 Td
(Arthritis Rheum 2000;43:2290-6. )Tj
31.25 46.25 Td
[(15. )-225 (Moll JM, )18 (W)40 (right )18 (V)129 (. New )37 (Y)100 (ork clinical criteria for ankylosing)]TJ
1.75 -1.25 Td
[(spondylitis. )55 (A)-220 (statistical evaluation. )55 (Ann Rheum Dis 1973;)]TJ
0 Tw T*
(32:354-63.)Tj
0.02499 Tw -1.75 -1.25 Td
[(16.)-500 (Lenkei R, )55 (Andersson B. Determination of the antibody binding)]TJ
1.75 -1.25 Td
(capacity of lymphocyte membrane antigens by flow cytometry in 58)Tj
T*
(blood donors. J Immunol Methods 1995;183:267-77.)Tj
-1.75 -1.25 Td
[(17.)-500 (Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell)]TJ
1.75 -1.25 Td
(progenitors in human blood. J Exp Med 1994;180:83-93.)Tj
-1.75 -1.25 Td
[(18.)-500 (van den Ber)18 (g )18 (WB, van Lent PLEM )18 (The role of macrophage in)]TJ
1.75 -1.25 Td
(chronic arthritis. Immunobiol 1996;195:614-23.)Tj
-1.75 -1.25 Td
[(19.)-500 (Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in)]TJ
1.75 -1.25 Td
(situ hybridization techniques in the examination of sacroiliac joint)Tj
T*
(biopsy specimens from patients with ankylosing spondylitis.)Tj
T*
(Arthritis Rheum 1995;38:499-505.)Tj
-1.75 -1.25 Td
[(20.)-500 (Hoogsteden HC, van Hal PT)74 (, )18 (W)40 (ijkhuijs JM, Hop )18 (W)92 (, Hilvering C.)]TJ
1.75 -1.25 Td
[(Expression of the CD1)37 (1/CD18 cell surface adhesion glycoprotein)]TJ
T*
(family and MHC class II antigen on blood monocytes and alveolar)Tj
T*
(macrophages in interstitial lung disease. Lung 1992;170:221-3.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(21.)-500 (T)70 (orsteinsdottir I, )55 (Arvidson NG, Hallgren R, Hakansson L. Monocyte)]TJ
0 Tc 1.75 -1.25 Td
(activation in rheumatoid arthritis, increased integrin, Fc gamma and)Tj
T*
[(complement receptor expression and the ef)18 (fect of glucocorticoids.)]TJ
T*
[(Clin Exp Immunol 1999:1)37 (15;554-60.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(22.)-500 (Benjamin RJ, Madrigal JA, Parham P)111 (. Peptide binding to empty)]TJ
0 Tc 1.75 -1.25 Td
(HLA-B27 molecules of viable human cells. Nature 1991;351:74-7.)Tj
-1.75 -1.25 Td
[(23.)-500 (Edwards JCW)92 (, Bowness P)111 (, )55 (Archer JR. Jekyll and Hyde: the)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(transformation of HLA-B27. Immunol )18 (T)70 (oday 2000;21:256-60.)]TJ
0 Tc -1.75 -1.25 Td
[(24.)-500 (Urben RG, Chicz RM, Lane )18 (WS, et al. )55 (A)-220 (subject of HLA-B27)]TJ
1.75 -1.25 Td
(molecules contains peptides much longer than nonamers. Proc Natl)Tj
T*
[(Acad Sci USA)-220 (1994;91:1534-8.)]TJ
-1.75 -1.25 Td
[(25.)-500 (Fukazawa )18 (T)74 (, Hermann E, Edidin M, et al. )18 (The ef)18 (fect of mutant beta)]TJ
1.75 -1.25 Td
(2-microglobulins on the conformation of HLA-B27 detected by)Tj
T*
(antibody and by CTL. J Immunol 1994;153:3543-50.)Tj
-1.75 -1.25 Td
[(26.)-500 (David CS. )18 (The mystery of HLA-B27 and disease. Immunogenetics)]TJ
0 Tw 1.75 -1.25 Td
(1997;46:73-7.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
154 0 obj
<>
endobj
272 0 obj
<>
endobj
103 0 obj
<>
endobj
108 0 obj
<>
endobj
109 0 obj
<>
endobj
131 0 obj
<>stream
HtV
PT}owYQ_(b"(TwQK lJ5 ĚT^d@M46VtNf_Xf̷{9} za-4L+hp_E\S"acˀŷ qĢM\ /<)䩅,[pBopM`R={Ƅiv 6CC]ŋ{*@}? rzHhi; rO{
EjV_nIZiM?}~QGm;&q=Z֟4nUAX
+z+2<fLE>"Cg ~c[]G[h×pc0
Q(u
{wܵZ1
a
9HEc֢^d E